170.00 +0.04 (0.02%)
After hours: 4:31PM EST
|Bid||167.52 x 100|
|Ask||170.74 x 500|
|Day's range||169.33 - 170.73|
|52-week range||138.83 - 191.10|
|PE ratio (TTM)||15.48|
|Earnings date||31 Jan 2018 - 5 Feb 2018|
|Forward dividend & yield||4.60 (2.71%)|
|1y target est||189.86|
GE isn’t the only household name I’m worried about. There is another popular dividend stock showing some very similar signs.
After rising 15.4% in the first nine months of the year, the Medical-Biotech /Genetics industry has declined 13.4% so far in the fourth quarter.
Biotech behemoths like Celgene and Gilead struggled in the third quarter, leaving room for nimble innovators like Neurocrine, Exelixis and Juno Therapeutics to swipe headlines after crushing expectations.
Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.
AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it. The U.S. Food and Drug Administration's (FDA) decision to endorse benralizumab, which will be marketed under the name Fasenra, follows a positive recommendation for the product in Europe on Friday. Shares (Berlin: DI6.BE - news) in AstraZeneca were 1 percent higher on Wednesday following the overnight news.
In 3Q17, Novartis’s Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ.
Amgen (AMGN) received positive CHMP opinion to expand Nplate's label to include pediatric patients and also for the marketing application of Avastin biosimilar.
Ligand's (LGND) earnings and revenues beat estimates. Total revenues also rise year over year on the back of higher royalty benefits. The company ups its guidance for 2017.
Of the 31 analysts tracking Celgene (CELG) in November 2017, 11 analysts recommended a “strong buy” while eight analysts recommended a “buy.”
Let’s talk about the only “market timing” strategy that actually works in practice – buying a stock before it announces a dividend hike.
In 3Q17, Amgen’s (AMGN) Enbrel generated revenues of around $1.36 billion, which reflected ~6% growth on year-over-year (or YoY) basis and ~7% growth on a quarter-over-quarter basis.
In 3Q17, Amgen’s (AMGN) Aranesp generated revenues of around $516 million, which reflected ~3% growth on a year-over-year (or YoY) basis and a ~4% decline on a quarter-over-quarter basis.
In 3Q17, Amgen’s (AMGN) Neulasta generated revenues of around $1.1 billion, a ~6% decline on a year-over-year (or YoY) basis and ~3% growth on a quarter-over-quarter basis.
In 3Q17, Amgen’s (AMGN) Prolia generated revenues of around $464 million, which reflected ~22% growth on a year-over-year (or YoY) basis and an 8% decline on a quarter-over-quarter basis.
In 3Q17, Amgen (AMGN) generated revenues of around $5.8 billion, a ~1% decline on a year-over-year (or YoY) basis and a ~1% decline on a quarter-over-quarter basis.
It was all about earnings this week with major biotech companies like Gilead (GILD), Celgene and Amgen reporting third quarter results.
Japan's Kirin Holdings Co Ltd said on Tuesday it would sell its share in a pharmaceutical research joint venture with California-based drugmaker Amgen Inc (AMGN.O) for $780 million. The joint venture, Kirin-Amgen, will buy the Japanese firm's 50 percent stake and will make further payments to Kirin for certain sales, the Japanese firm said in a statement, adding that the companies saw their collaboration as complete. Established in 1984 to fund the development of the kidney disease drug Epogen, the joint venture's scope grew to include, among others, the white blood cell-boosting drugs Neupogen and Neulasta, used during chemotherapy treatment, Amgen said in a separate statement.